The World Health Organization on Wednesday resumed testing hydroxychloroquine, reversing its decision to halt trials of the well-known anti-malaria drug, after a global study of 96,000 hospital cases of Corona Virus that concluded HCQ had no benefit against the disease, was shown to be a complete fraud.
Of the two authors of the study, one was revealed to be running a flim-flam research outfit that never actually contacted any of the 671 hospitals for their patient data, while the other is employed by a hospital being paid to test rival drug Remdesivir, the expensive competing remedy from stalwart pharmaceutical industrial complex firm, Gilead.
The study was published on May 22nd to much fanfare in the leading global medical journals, the UK’s Lancet and New England Journal of Medicine, confirming the Establishment’s conventional wisdom and media consensus that HCQ was ineffective against Corona Virus and actually encouraged heart ailments in patients.
But the analysis fell apart as scientists began to scrutinize its methods and after an exposé in the British Guardian reported that hospitals denied to the newspaper that they had ever contributed patient data to the study or been contacted by research firm Surgisphere.
The entire premise — that 671 hospitals out of a 1,200-hospital database contributed data from 96,000 patients — was also ridiculed by professionals in government integration consultancies. Basically, getting the data send approved, scrubbed, sent, organized, collated and reviewed would be the work of entire government departments for months, rather than feasible by a small company with a dozen employees, few of them actual scientists or doctors, and unable to show they ever contacted the hospitals for the data, or how the task was completed in just weeks.
Surgisphere Corporation founder and CEO Dr. Sapan Desai refused to disclose the data for independent confirmatory review or name the participating hospitals or countries in the report.
Dr. Mandeep Mehra, the lead co-author is a director at Boston’s Brigham & Women’s Hospital, which is credited with funding the study. Dr. Mehra and The Lancet failed to disclose that Brigham Hospital has a partnership with Gilead and is currently conducting two trials testing Remdesivir, the prime competitor of hydroxychloroquine for the treatment of COVID-19, the focus of the study.
Remdesivir has been criticized as being both far less effective — if effective at all — compared to HCQ, as well as the price of its proposed pill, expected to be an exorbitant $1,000 per pill versus HCQ’s generic price of $0.64. Remdesivir-backer Gilead is becoming known now mainly for finding non-working solutions to major pandemic outbreaks and being behind the biggest HIV drug; former Defense Secretary Donald Rumsfeld is one of its leading investors.
At a press conference on Wednesday, the WHO announced it would resume its global trial of HCQ, after its data safety monitoring committee found there was no increased risk of death for Corona Virus patients taking it.
WHO director general Dr Tedros Adhanom Ghebreyesus said that all parts of the Solidarity trial would go ahead, testing multiple cures on more than 3,500 patients recruited froim 35 countries.
“On the basis of the available mortality data, the members of the committee recommended that there are no reasons to modify the trial protocol,” said Tedros. “The executive group received this recommendation and endorsed continuation of all arms of the Solidarity trial, including hydroxychloroquine.”
Americans following the testing closely have learned that, for years, scientists have known that HCQ also fighting Cancer, Arthritis and even Diabetes, that its basic ingredient — quinine — can be made at home, and on Monday that U.S. President Donald J. Trump has been popping the pill daily.
Globally, Costa Rican health officials determined HCQ was the right course of treatment for their at-risk and infected population after its embassy in China organized a video-conference with health officials there who said the cheap pill “was used in Shanghai as the first line of treatment,” in the words of Mario Ruiz, medical director of their system.
And doctors in India found that the reason HCQ and Zinc work against the virus, is not that it kills the virus that attacks the immune system, but the bacteria is enabled by it, and that bacteria is the real killer.
— Dr Vladimir (Zev) Zelenko (@zev_dr) June 4, 2020
Despite the advances on fighting the disease and the drop in new cases, the race for a vaccine continued.
The U.S. should have 100 million doses of one potential virus vaccine by the end of the year, Dr. Anthony Fauci, the director of the National Institute of Allergy and Infectious Diseases and a member of the White House Task Force, on Tuesday told a Q&A with the Journal of the American Medical Association.
“Then, by the beginning of 2021, we hope to have a couple hundred million doses,” Fauci said, according to Epoch Times.
Fauci said the first vaccine candidate, made by biotech company Moderna in partnership with NIAID, should go into a final stage of trials in volunteers, known as Phase 3, by mid-summer. Preparations at national and international sites are already underway, he said.